News: Additional ICD-10-PCS codes added
January 27, 2022
CDI Strategies - Volume 16, Issue 4
In response to the continued COVID-19 pandemic, CMS has released two additional ICD-10-PCS procedural codes, effective April 1, 2022. The codes have also been added to V39.1 MS-DRGs.
The additional codes are:
- XW024X7 – Introduction of tixagevimab and cilgavimab monoclonal antibody into muscle, percutaneous approach, new technology group 7
- XW023Y7 – Introduction of other new technology monoclonal antibody into muscle, percutaneous approach, new technology group 7
Tixagevimab and cilgavimab monoclonal antibody is also known by the name of Evusheld. Both additional codes are designated as non-OR procedures within the MS-DRG system.
The additional procedural codes are released following suit of CMS’ release of seven COVID-19-related procedure codes in November, 2021, after the final ruling.
Editor’s note: The CMS code update can be found here.